Some founders build startups to exit. GT Medical Technologies was built to save lives, and maybe, just maybe, to make the phrase “inoperable brain tumor” obsolete.
Let’s rewind to 2011. Five brain tumor specialists at Barrow Neurological Institute didn’t set out to disrupt. They set out to fix something. Radiation delays after brain surgery weren’t just inconvenient, they were lethal. So they built a better solution from scratch. In 2017, GT Medical Technologies was born to bring it to the world. This week? They just locked in a $53 million Series D that says they’re not just surviving, they’re scaling.
Two closes. One mission. First came $37 million in January, led by Evidity Health Capital with Accelmed Partners joining the mission and MVM Partners, Gilde Healthcare, and MedTech Venture Partners doubling down. Then another $16 million this July, courtesy of FemHealth Ventures, Warren Point Capital, and a hush-hush strategic player with skin in the game. Let’s just say the cap table isn’t just institutional, it’s surgical.
Big congrats to Chief Executive Officer Per Langoe and Chief Technology Officer Dr. David G. Brachman, MD, FASTRO. When you’ve got a CEO who scaled Palette Life Sciences to a $600 million exit and a CTO who co-invented the product that’s already in over 100 hospitals, that’s not a team, it’s a clinic in momentum.
GammaTile Therapy isn’t your average medtech pitch deck fantasy. It’s an FDA-cleared, surgically targeted radiation therapy delivering Cesium-131 straight to the resection site. No waiting, no margin for error. Over 1,900 patients treated. More than 800 enrolled in clinical studies. Not some pilot, it’s a platform.
GT Medical isn’t just growing its sales team. They’re expanding clinical trials (ROADS and GESTALT are in motion), deepening hospital penetration, and creating Centers of Excellence like USC Brain Tumor Center and AdventHealth Orlando. They’re also hiring across engineering and project management to fuel that next phase.
The business lesson? When the product starts in the OR and ends in saving time, tissue, and lives, you don’t need hype. You need execution. Investors know it. ELITE hospitals know it. Now the rest of the market’s catching on.
This isn’t a story about medtech. It’s a story about what happens when you stop accepting the status quo and start implanting change, one tile at a time.
